Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31255687)

  • 1. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
    Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Effect of a Mesothelin-Targeted
    Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
    J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
    Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
    Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
    Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
    Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
    Sommer A; Kopitz C; Schatz CA; Nising CF; Mahlert C; Lerchen HG; Stelte-Ludwig B; Hammer S; Greven S; Schuhmacher J; Braun M; Zierz R; Wittemer-Rump S; Harrenga A; Dittmer F; Reetz F; Apeler H; Jautelat R; Huynh H; Ziegelbauer K; Kreft B
    Cancer Res; 2016 Nov; 76(21):6331-6339. PubMed ID: 27543601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
    Hagemann UB; Wickstroem K; Wang E; Shea AO; Sponheim K; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS
    Mol Cancer Ther; 2016 Oct; 15(10):2422-2431. PubMed ID: 27535972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
    Lejeune P; Cruciani V; Berg-Larsen A; Schlicker A; Mobergslien A; Bartnitzky L; Berndt S; Zitzmann-Kolbe S; Kamfenkel C; Stargard S; Hammer S; Jørgensen JS; Jackerott M; Nielsen CH; Schatz CA; Hennekes H; Karlsson J; Cuthbertson AS; Mumberg D; Hagemann UB
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
    Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
    BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
    Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
    Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
    Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.
    Hammer S; Schlicker A; Zitzmann-Kolbe S; Baumgart S; Hagemann UB; Scholz A; Haendler B; Lejeune P; Karlsson J; Ellingsen C; Hennekes H; Nielsen CH; Juul MU; Mumberg D; Schatz CA
    Clin Cancer Res; 2021 Aug; 27(15):4367-4378. PubMed ID: 34035067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
    Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
    Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
    PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in
    Hagemann UB; Mihaylova D; Uran SR; Borrebaek J; Grant D; Bjerke RM; Karlsson J; Cuthbertson AS
    Oncotarget; 2017 Aug; 8(34):56311-56326. PubMed ID: 28915592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    Wickstroem K; Karlsson J; Ellingsen C; Cruciani V; Kristian A; Hagemann UB; Bjerke RM; Ryan OB; Linden L; Mumberg D; Brands M; Cuthbertson A
    Pharmaceuticals (Basel); 2019 Oct; 12(4):. PubMed ID: 31618864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.